Application of Shouwu Yizhi prescription in decubation of patients with ischemic stroke

ABSTRACT

We investigate the application of Shouwu Yizhi prescription (SYP) in decubation of patients with ischemic stroke (IS). The clinical data of 106 patients recovering from IS who came to our hospital from December 2019 to December 2020 were selected for retrospective analysis, and they were separated into experimental group (n = 53, basic treatment + SYP) and control group (n = 53, basic treatment) based on the principle of random grouping. The clinical indexes such as lipid indexes and neurological disability score (NDS) after treatment were compared between both groups to comprehensively evaluate the clinical effects of different treatment regimens. Except for high-density lipoprotein cholesterol value, the lipid indexes in the experimental group after treatment were remarkably lower than those in the control group (P < 0.001). After treatment, the levels of hypersensitive C-reactive protein, homocysteine and lipoprotein-associated phospholipase A2 were remarkably lower in the experimental group than control group (P < 0.05). After treatment, the experimental group had remarkably higher mean scores of Montreal Cognitive Assessment, Fugl-Meyer Assessment in upper and lower limbs and lower NDS than control group (P < 0.001). SYP is an efficient treatment plan in decubation of IS, which can effectively improve the blood lipid indexes and neurological function of patients, and further studies will help establish a better solution for such patients.

KEYWORDS:

• Shouwu Yizhi prescription (SYP)
• ischemic stroke (IS)
• decubation
• application

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This research was funded by Shandong Provincial Natural Science Foundation, grant numbers ZR2021MH386, ZR2021LZY028 and ZR2015PH046, Youth Program of National Natural Science Foundation of China, grant number 81302940, Shandong Qianfo Mountain Hospital National Natural Science Foundation, grant number QYPY2020NSFC0619, National Natural Science Foundation of China, grant number 30873323 and Technology and Development Program of Traditional Chinese Medicine, Shandong Province, grant numbers 2011-192, 2013ZDZK-091 and 2015-281.

Notes on contributors

Chao Chen

Chao Chen, male, M.D. Mainly engaged in clinical research on the integration of traditional Chinese and Western medicine. Research direction: Integrated traditional Chinese and Western medicine for the treatment of cerebrovascular diseases and geriatric internal medicine diseases.

Guangqing Cheng

Guangqing Cheng, male, Master, Engaged in clinical work of traditional Chinese medicine for 25 years, proficient in the diagnosis and treatment of cardiovascular and cerebrovascular diseases, geriatric diseases, spleen, stomach, liver and gallbladder diseases, and exogenous diseases in traditional Chinese medicine. Research direction: prevention and treatment of atherosclerotic plaque formation with traditional Chinese and western medicine, diagnosis and treatment of vertigo.

Ruiqi Jia

Ruiqi Jia, female, Master of medicine, The Traditional Chinese Medicine Department of Shandong Provincial Police Officer General Hospital, Mainly engages in clinical research on the integration of traditional Chinese and Western medicine. Research direction: The treatment of cerebrovascular diseases and internal medicine diseases through the integration of traditional Chinese and Western medicine.

Aishuai Wang

Aishuai Wang, male, M.D. Traditional Chinese Medicine Internal Medicine (Diagnosis and Treatment of Lung Cancer with Integrated Traditional Chinese and Western Medicine).

Anrong Wang

Anrong Wang, female, M.D. Research direction: Diagnosis and treatment of nervous system disease with integrated traditional Chinese and western medicine.

Xiaoni Yang

Xiaoni Yang, female, M.D. Mainly engaged in clinical research on the integration of traditional Chinese and Western medicine. Research direction: Treatment of Cardiovascular and Cerebrovascular Diseases and Elderly Internal Medicine Diseases through the Combination of Traditional Chinese and Western Medicine.